Century Therapeutics (IPSC) Stock Forecast, Price Target & Predictions
IPSC Stock Forecast
Century Therapeutics stock forecast is as follows: an average price target of $20.00 (represents a 1150.00% upside from IPSC’s last price of $1.60) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
IPSC Price Target
The average price target for Century Therapeutics (IPSC) is $20.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $27.00 to $9.00. This represents a potential 1150.00% upside from IPSC's last price of $1.60.
IPSC Analyst Ratings
According to 6 Wall Street analysts, Century Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for IPSC stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Century Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 12, 2024 | Edward Tenthoff | Piper Sandler | $9.00 | $4.05 | 122.22% | 462.50% |
| Jan 05, 2023 | Edward Tenthoff | Piper Sandler | $14.00 | $4.84 | 189.26% | 775.00% |
| Dec 27, 2022 | Geulah Livshits | Chardan Capital | $19.00 | $5.67 | 235.10% | 1087.50% |
| Nov 14, 2022 | - | H.C. Wainwright | $25.00 | $11.00 | 127.27% | 1462.50% |
| Apr 29, 2022 | - | Leerink Partners | $27.00 | $12.03 | 124.44% | 1587.50% |
The latest Century Therapeutics stock forecast, released on Apr 12, 2024 by Edward Tenthoff from Piper Sandler, set a price target of $9.00, which represents a 122.22% increase from the stock price at the time of the forecast ($4.05), and a 462.50% increase from IPSC last price ($1.60).
Century Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $9.00 |
| Last Closing Price | $1.60 | $1.60 | $1.60 |
| Upside/Downside | -100.00% | -100.00% | 462.50% |
In the current month, the average price target of Century Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Century Therapeutics's last price of $1.60. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 15, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 08, 2024 | Rodman & Renshaw | - | Buy | Initialise |
| Jun 17, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 04, 2024 | Piper Sandler | Buy | Buy | Hold |
| Jun 04, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Apr 12, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 28, 2023 | Needham | - | Neutral | Downgrade |
| Aug 10, 2023 | Chardan Capital | Buy | Buy | Hold |
| Jan 06, 2023 | SVB Leerink | Outperform | Outperform | Hold |
| Jan 05, 2023 | Piper Sandler | Overweight | Overweight | Hold |
Century Therapeutics's last stock rating was published by H.C. Wainwright on Aug 15, 2024. The company gave IPSC a "Buy" rating, the same as its previous rate.
Century Therapeutics Financial Forecast
Century Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $148.00K | $99.00K | $1.72M | $521.00K | $2.22M | - | $1.06M |
| Avg Forecast | $1.00M | $1.00M | $1.00M | $1.00M | $680.00K | $680.00K | $580.00K | $580.00K | $440.00K | $440.00K | $430.00K | $210.00K | $1.67M | $1.32M | $1.14M | $1.47M | $2.00M | $1.08M | $1.34M | $10.00M |
| High Forecast | $3.92M | $3.92M | $3.92M | $3.92M | $2.67M | $2.67M | $2.27M | $2.27M | $1.73M | $936.17K | $1.69M | $823.37K | $4.65M | $5.16M | $4.47M | $5.78M | $7.85M | $4.24M | $1.34M | $16.67M |
| Low Forecast | $49.50K | $49.50K | $49.50K | $49.50K | $33.66K | $33.66K | $28.71K | $28.71K | $21.78K | $93.62K | $21.29K | $10.40K | $98.72K | $65.16K | $56.50K | $72.96K | $99.17K | $53.59K | $1.34M | $3.33M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.11% | 0.09% | 1.17% | 0.26% | 2.05% | - | 0.11% |
Century Therapeutics's average Quarter revenue forecast for Dec 23 based on 5 analysts is $1.67M, with a low forecast of $98.72K, and a high forecast of $4.65M. IPSC's average Quarter revenue forecast represents a 1027.22% increase compared to the company's last Quarter revenue of $148.00K (Sep 23).
Century Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-35.63M | $-35.08M | $-29.65M | $-28.49M | $-27.65M | - | $-36.10M |
| Avg Forecast | $200.00K | $200.00K | $200.00K | $200.00K | $136.00K | $136.00K | $116.00K | $116.00K | $88.00K | $88.00K | $86.00K | $42.00K | $333.66K | $263.25K | $228.25K | $294.75K | $400.66K | $216.50K | $267.60K | $-21.18M |
| High Forecast | $784.16K | $784.16K | $784.16K | $784.16K | $533.23K | $533.23K | $454.81K | $454.81K | $345.03K | $187.23K | $337.19K | $164.67K | $929.90K | $1.03M | $894.92K | $1.16M | $1.57M | $848.85K | $267.60K | $-16.94M |
| Low Forecast | $9.90K | $9.90K | $9.90K | $9.90K | $6.73K | $6.73K | $5.74K | $5.74K | $4.36K | $18.72K | $4.26K | $2.08K | $19.74K | $13.03K | $11.30K | $14.59K | $19.83K | $10.72K | $267.60K | $-25.41M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -135.33% | -153.68% | -100.60% | -71.12% | -127.73% | - | 1.70% |
undefined analysts predict IPSC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Century Therapeutics's previous annual EBITDA (undefined) of $NaN.
Century Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-32.72M | $-33.29M | $-31.26M | $-31.68M | $-30.75M | - | $-37.51M |
| Avg Forecast | $-46.08M | $-45.16M | $-44.66M | $-44.06M | $-38.75M | $-37.60M | $-39.24M | $-38.25M | $-38.09M | $-36.94M | $-37.34M | $-42.13M | $-44.96M | $-42.79M | $-44.64M | $-42.99M | $-47.79M | $-48.80M | $-31.15M | $-22.01M |
| High Forecast | $10.86M | $10.64M | $10.52M | $10.38M | $9.13M | $8.86M | $9.25M | $9.01M | $8.98M | $-32.93M | $8.80M | $9.93M | $-35.66M | $10.08M | $10.52M | $10.13M | $11.26M | $11.50M | $-31.15M | $-17.61M |
| Low Forecast | $-221.04M | $-216.63M | $-214.23M | $-211.35M | $-185.87M | $-180.36M | $-188.24M | $-183.51M | $-182.72M | $-40.96M | $-179.12M | $-202.08M | $-54.26M | $-205.27M | $-214.13M | $-206.24M | $-229.25M | $-234.09M | $-31.15M | $-26.41M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.76% | 0.75% | 0.73% | 0.66% | 0.63% | - | 1.70% |
Century Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IPSC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Century Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $8.99M | $8.23M | $8.90M | $8.24M | $8.06M | - | $7.30M |
| Avg Forecast | $3.76M | $3.76M | $3.76M | $3.76M | $2.56M | $2.56M | $2.18M | $2.18M | $1.66M | $1.66M | $1.62M | $790.43K | $6.28M | $4.95M | $4.30M | $5.55M | $7.54M | $4.07M | $5.04M | $4.28M |
| High Forecast | $14.76M | $14.76M | $14.76M | $14.76M | $10.04M | $10.04M | $8.56M | $8.56M | $6.49M | $3.52M | $6.35M | $3.10M | $17.50M | $19.42M | $16.84M | $21.75M | $29.56M | $15.98M | $5.04M | $5.14M |
| Low Forecast | $186.33K | $186.33K | $186.33K | $186.33K | $126.70K | $126.70K | $108.07K | $108.07K | $81.99K | $352.37K | $80.12K | $39.13K | $371.56K | $245.26K | $212.65K | $274.61K | $373.28K | $201.71K | $5.04M | $3.43M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.81% | 1.92% | 1.60% | 1.09% | 1.98% | - | 1.70% |
Century Therapeutics's average Quarter SG&A projection for Dec 23 is $6.28M, based on 5 Wall Street analysts, with a range of $371.56K to $17.50M. The forecast indicates a -30.12% fall compared to IPSC last annual SG&A of $8.99M (Sep 23).
Century Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.55 | $-0.56 | $-0.53 | $-0.55 | $-0.53 | - | $-0.66 |
| Avg Forecast | $-0.56 | $-0.55 | $-0.54 | $-0.54 | $-0.47 | $-0.46 | $-0.48 | $-0.47 | $-0.46 | $-0.45 | $-0.45 | $-0.51 | $-0.55 | $-0.52 | $-0.54 | $-0.52 | $-0.58 | $-0.59 | $-0.50 | $-0.45 |
| High Forecast | $0.13 | $0.13 | $0.13 | $0.13 | $0.11 | $0.11 | $0.11 | $0.11 | $0.11 | $-0.40 | $0.11 | $0.12 | $-0.43 | $0.12 | $0.13 | $0.12 | $0.14 | $0.14 | $-0.50 | $-0.06 |
| Low Forecast | $-2.69 | $-2.64 | $-2.61 | $-2.57 | $-2.26 | $-2.20 | $-2.29 | $-2.24 | $-2.23 | $-0.50 | $-2.18 | $-2.46 | $-0.66 | $-2.50 | $-2.61 | $-2.51 | $-2.79 | $-2.85 | $-0.50 | $-0.84 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.03% | 1.01% | 0.94% | 0.89% | - | 1.46% |
According to undefined Wall Street analysts, Century Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IPSC previous annual EPS of $NaN (undefined).
Century Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KZR | Kezar Life Sciences | $0.57 | $17.50 | 2970.18% | Buy |
| IPSC | Century Therapeutics | $1.60 | $20.00 | 1150.00% | Buy |
| NGM | NGM Biopharmaceuticals | $1.54 | $16.50 | 971.43% | Buy |
| PASG | Passage Bio | $0.81 | $6.00 | 640.74% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| NKTX | Nkarta | $5.71 | $21.60 | 278.28% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| RLAY | Relay Therapeutics | $7.60 | $19.50 | 156.58% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| ERAS | Erasca | $2.97 | $7.00 | 135.69% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| KROS | Keros Therapeutics | $56.98 | $105.00 | 84.28% | Buy |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| CCCC | C4 Therapeutics | $6.44 | $11.33 | 75.93% | Hold |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
IPSC Forecast FAQ
Is Century Therapeutics a good buy?
Yes, according to 6 Wall Street analysts, Century Therapeutics (IPSC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 83.33% of IPSC's total ratings.
What is IPSC's price target?
Century Therapeutics (IPSC) average price target is $20 with a range of $9 to $27, implying a 1150.00% from its last price of $1.6. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Century Therapeutics stock go up soon?
According to Wall Street analysts' prediction for IPSC stock, the company can go up by 1150.00% (from the last price of $1.6 to the average price target of $20), up by 1587.50% based on the highest stock price target, and up by 462.50% based on the lowest stock price target.
Can Century Therapeutics stock reach $2?
IPSC's average twelve months analyst stock price target of $20 supports the claim that Century Therapeutics can reach $2 in the near future.
What are Century Therapeutics's analysts' financial forecasts?
Century Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.52M (high $9.88M, low $124.75K), average EBITDA is $504K (high $1.98M, low $24.95K), average net income is $-154M (high $36.25M, low $-738M), average SG&A $9.49M (high $37.19M, low $469.55K), and average EPS is $-1.874 (high $0.442, low $-8.99). IPSC's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $4M (high $15.68M, low $198.02K), average EBITDA is $800K (high $3.14M, low $39.6K), average net income is $-180M (high $42.41M, low $-863M), average SG&A $15.06M (high $59.03M, low $745.32K), and average EPS is $-2.192 (high $0.517, low $-10.516).
Did the IPSC's actual financial results beat the analysts' financial forecasts?
Based on Century Therapeutics's last annual report (Dec 2023), the company's revenue was $2.24M, which missed the average analysts forecast of $5.6M by -60.09%. Apple's EBITDA was $-147M, missing the average prediction of $1.12M by -13185.59%. The company's net income was $-137M, missing the average estimation of $-175M by -22.07%. Apple's SG&A was $34.71M, beating the average forecast of $21.08M by 64.67%. Lastly, the company's EPS was $-0.0023, missing the average prediction of $-2.136 by -99.89%. In terms of the last quarterly report (Sep 2023), Century Therapeutics's revenue was $148K, missing the average analysts' forecast of $1.32M by -88.76%. The company's EBITDA was $-35.626M, missing the average prediction of $263.25K by -13633.19%. Century Therapeutics's net income was $-32.72M, missing the average estimation of $-42.791M by -23.53%. The company's SG&A was $8.99M, beating the average forecast of $4.95M by 81.38%. Lastly, the company's EPS was $-0.55, beating the average prediction of $-0.521 by 5.52%